Molecular Mechanisms of Cardiac Amyloidosis

Cardiac involvement has a profound effect on the prognosis of patients with systemic amyloidosis. Therapeutic methods for suppressing the production of causative proteins have been developed for ATTR amyloidosis and AL amyloidosis, which show cardiac involvement, and the prognosis has been improved....

Full description

Saved in:
Bibliographic Details
Published inInternational journal of molecular sciences Vol. 23; no. 1; p. 25
Main Authors Saito, Yukihiro, Nakamura, Kazufumi, Ito, Hiroshi
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 21.12.2021
MDPI
Subjects
Aging
Alzheimer's disease
amyloid
Amyloid Neuropathies, Familial - pathology
Amyloid precursor protein
Amyloidosis
Animals
Cardiomyopathies - pathology
Cardiomyopathy
Cytotoxicity
Gender differences
Gene expression
Heart
Heart - physiopathology
Humans
immunoglobulin light chain
Immunoglobulin Light-chain Amyloidosis - pathology
Molecular modelling
Mutation
Physiology
Production methods
Prognosis
Proteins
Review
Shear stress
Transgenic animals
transthyretin
amyloid
immunoglobulin light chain
transthyretin
cytotoxicity
Online AccessGet full text

Cover

More Information
Summary:Cardiac involvement has a profound effect on the prognosis of patients with systemic amyloidosis. Therapeutic methods for suppressing the production of causative proteins have been developed for ATTR amyloidosis and AL amyloidosis, which show cardiac involvement, and the prognosis has been improved. However, a method for removing deposited amyloid has not been established. Methods for reducing cytotoxicity caused by amyloid deposition and amyloid precursor protein to protect cardiovascular cells are also needed. In this review, we outline the molecular mechanisms and treatments of cardiac amyloidosis.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms23010025